• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.

作者信息

Sawicki Gregory S, McKone Edward F, Millar Stefanie J, Pasta David J, Konstan Michael W, Lubarsky Barry, Wagener Jeffrey S

机构信息

1 Boston Children's Hospital Boston, Massachusetts.

2 Harvard Medical School Boston, Massachusetts.

出版信息

Am J Respir Crit Care Med. 2017 Jun 15;195(12):1673-1676. doi: 10.1164/rccm.201608-1678LE.

DOI:10.1164/rccm.201608-1678LE
PMID:28617084
Abstract
摘要

相似文献

1
Patients with Cystic Fibrosis and a G551D or Homozygous F508del Mutation: Similar Lung Function Decline.患有囊性纤维化且携带G551D或纯合F508del突变的患者：肺功能下降情况相似。
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1673-1676. doi: 10.1164/rccm.201608-1678LE.
2
Clinical phenotype of cystic fibrosis patients with the G551D mutation.囊性纤维化患者 G551D 突变的临床表型。
QJM. 2009 Nov;102(11):793-8. doi: 10.1093/qjmed/hcp120. Epub 2009 Sep 4.
3
Impact of MIF gene promoter polymorphism on F508del cystic fibrosis patients.巨噬细胞移动抑制因子（MIF）基因启动子多态性对F508del型囊性纤维化患者的影响。
PLoS One. 2014 Dec 12;9(12):e114274. doi: 10.1371/journal.pone.0114274. eCollection 2014.
4
Heterogeneity of phenotype in two cystic fibrosis patients homozygous for the CFTR exon 11 mutation G551D.两名囊性纤维化患者均为CFTR外显子11突变G551D的纯合子，其表型存在异质性。
J Med Genet. 1996 Aug;33(8):711-3. doi: 10.1136/jmg.33.8.711.
5
Year to year change in FEV in patients with cystic fibrosis and different mutation classes.囊性纤维化患者及不同突变类型患者的第一秒用力呼气容积逐年变化。
J Cyst Fibros. 2017 Mar;16(2):239-245. doi: 10.1016/j.jcf.2016.09.009. Epub 2016 Oct 11.
6
Overweight and obesity in deltaF508 homozygous cystic fibrosis.ΔF508纯合型囊性纤维化患者的超重与肥胖
J Pediatr. 2005 Sep;147(3):402-4. doi: 10.1016/j.jpeds.2005.06.003.
7
Ivacaftor in a G551D homozygote with cystic fibrosis.依伐卡托用于治疗一名患有囊性纤维化的G551D纯合子患者。
N Engl J Med. 2013 Sep 26;369(13):1280-2. doi: 10.1056/NEJMc1213681.
8
Lung function decline is delayed but not decreased in patients with cystic fibrosis and the R117H gene mutation.囊性纤维化患者和 R117H 基因突变患者的肺功能下降延迟但不减少。
J Cyst Fibros. 2018 Jul;17(4):503-510. doi: 10.1016/j.jcf.2017.10.003. Epub 2017 Oct 31.
9
Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.临床试验和囊性纤维化患者注册数据相结合证明伊伐卡托持续获益。
Am J Respir Crit Care Med. 2015 Oct 1;192(7):836-42. doi: 10.1164/rccm.201503-0578OC.
10
Cystic fibrosis co-existing with trisomy 21.囊性纤维化合并 21 三体。
J Cyst Fibros. 2010 Sep;9(5):330-1. doi: 10.1016/j.jcf.2010.05.003. Epub 2010 Jun 11.

引用本文的文献

1
Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.伊伐卡托对囊性纤维化患者和特定伊伐卡托反应性突变体的真实世界影响。
BMJ Open Respir Res. 2024 Jul 29;11(1):e002033. doi: 10.1136/bmjresp-2023-002033.
2
Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis.依伐卡托对囊性纤维化患者死亡率和健康结果的长期影响。
Thorax. 2024 Sep 18;79(10):925-933. doi: 10.1136/thorax-2023-220558.
3
Using Negative Control Outcomes and Difference-in-Differences Analysis to Estimate Treatment Effects in an Entirely Treated Cohort: The Effect of Ivacaftor in Cystic Fibrosis.
利用阴性对照结局和双重差分分析在全治疗队列中估计治疗效果：依伐卡托特在囊性纤维化中的作用。
Am J Epidemiol. 2022 Feb 19;191(3):505-515. doi: 10.1093/aje/kwab263.
4
Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review.依伐卡托治疗囊性纤维化患者的真实世界结局：一项系统评价
J Clin Med. 2021 Apr 6;10(7):1527. doi: 10.3390/jcm10071527.
5
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.G551D 突变型 CFTR 患者使用伊伐卡托的长期临床疗效。
J Cyst Fibros. 2021 Mar;20(2):213-219. doi: 10.1016/j.jcf.2020.11.008. Epub 2020 Nov 25.
6
Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study.依伐卡托特治疗囊性纤维化伴 G551D 突变患者的患者报告结局：一项横断面研究的结果。
BMC Pulm Med. 2019 Aug 13;19(1):146. doi: 10.1186/s12890-019-0887-6.
7
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.来自美国和英国囊性纤维化注册中心的数据支持 CFTR 调节剂 ivacaftor 对疾病的修饰作用。
Thorax. 2018 Aug;73(8):731-740. doi: 10.1136/thoraxjnl-2017-210394. Epub 2018 May 10.
8
Poor recovery from a pulmonary exacerbation does not lead to accelerated FEV decline.肺部病情加重后恢复不佳不会导致第一秒用力呼气容积加速下降。
J Cyst Fibros. 2017 Jul 29. doi: 10.1016/j.jcf.2017.07.003.